The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort
Open accessAbstract
BACKGROUND: The natural history of prostate cancer is highly variable and it is difficult to predict. We showed previously that a cell cycle progression (CCP) score was a robust predictor of outcome in a conservatively managed cohort diagnosed by transurethral resection of the prostate. A greater need is to predict outcome in patients diagnosed by needle biopsy. METHODS: Total RNA was extracted from paraffin specimens. A CCP score was calculated from expression levels of 31 genes. Clinical variables consisted of centrally re-reviewed Gleason score, baseline prostate-specific antigen level, age, clinical stage, and extent of disease. The primary endpoint was death from prostate cancer. RESULTS: In univariate analysis (n=349), the hazard ratio (HR) for death from prostate cancer was 2.02 (95% CI (1.62, 2.53), P<10(-9)) for a one-unit increase in CCP score. The CCP score was only weakly correlated with standard prognostic factors and in a multivariate analysis, CCP score dominated (HR for one-unit increase=1.65, 95% CI (1.31, 2.09), P=3 × 10(-5)), with Gleason score (P=5 × 10(-4)) and prostate-specific antigen (PSA) (P=0.017) providing significant additional contributions. CONCLUSION: For conservatively managed patients, the CCP score is the strongest independent predictor of cancer death outcome yet described and may prove valuable in managing clinically localised prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Etzioni, R. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.13.981 · Cited by 949
Cuzick, J., Swanson, G. P., Fisher, G., Brothman, A. R., Berney, D. M., Reid, J. E., Mesher, D., Speights, V., Stankiewicz, E., Foster, C. S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70295-3 · Cited by 792
Self-citationBreslow, N., Chan, C. W., Dhom, G., Drury, R. A. B., Franks, L. M., Gellei, B., Lee, Y. S., Lundberg, S., Sparke, B., Sternbya, N. H., et al. (1977) · International Journal of Cancer · doi:10.1002/ijc.2910200506 · Cited by 584
Sakr, W. A., Grignon, D. J., Crissman, J. D., Heilbrun, L. K., Cassin, B. J., Pontes, J. J., & Haas, G. P. (1994) · PubMed · Cited by 575
Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force
Chou, R., Croswell, J. M., Dana, T., Bougatsos, C., Blazina, I., Fu, R., Gleitsmann, K., Koenig, H. C., Lam, C., Maltz, A., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-11-201112060-00375 · Cited by 573
Changes in prostate cancer incidence and treatment in USA
Lu-Yao, G. L., & Greenberg, E. R. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91109-6 · Cited by 248
Sánchez‐Chapado, M., Olmedilla, G., Cabeza, M., Donat, E., & Ruiz, A. (2003) · The Prostate · doi:10.1002/pros.10177 · Cited by 165
Long-term outcome among men with conservatively treated localised prostate cancer
on behalf of the Transatlantic Prostate Group, Cuzick, J. M., Fisher, G., Kattan, M. W., Berney, D. M., Oliver, R. T. D., Foster, C. S., Møller, H., Reuter, V., Fearn, P., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603411 · Cited by 134
Self-citationThe Prevalence of Prostate Carcinoma and Its Precursor in Hungary: An Autopsy Study
Soós, G., TSAKIRIS, I., Szántó, J., Turzó, C., Haas, P., & Dezsö, B. (2005) · European Urology · doi:10.1016/j.eururo.2005.08.010 · Cited by 130
Prostate carcinoma incidence and patient mortality
Brawley, O. W. (1997) · Cancer · Cited by 127
Construction of tissue microarrays from prostate needle biopsy specimens
Jhavar, S. G., Corbishley, C. M., Dearnaley, D. P., Fisher, C., Falconer, A., Parker, C. C., Eeles, R. A., & Cooper, C. S. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602726 · Cited by 33
Cited by
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Mohler, J. L., Antonarakis, E. S., Armstrong, A. J., D’Amico, A. V., Davis, B. J., Dorff, T., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0023 · Cited by 1,532
Genomic correlates of clinical outcome in advanced prostate cancer
Abida, W., Cyrta, J., Heller, G., Prandi, D., Armenia, J., Coleman, I., Cieslik, M., Benelli, M., Robinson, D., Van Allen, E. M., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902651116 · Cited by 1,372
Rebello, R. J., Oing, C., Knudsen, K. E., Loeb, S., Johnson, D. C., Reiter, R. E., Gillessen, S., Van der Kwast, T., & Bristow, R. G. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00243-0 · Cited by 1,090
Genetics and biology of prostate cancer
Wang, G., Zhao, D., Spring, D. J., & DePinho, R. A. (2018) · Genes & Development · doi:10.1101/gad.315739.118 · Cited by 750
Klein, E. A., Cooperberg, M. R., Magi-Galluzzi, C., Simko, J. P., Falzarano, S. M., Maddala, T., Chan, J. M., Li, J., Cowan, J. E., Tsiatis, A. C., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.05.004 · Cited by 659
Metadata
- Authors
- on behalf of the Transatlantic Prostate Group, Cuzick, J., Berney, D. M., Fisher, G., Mesher, D., Møller, H., Reid, J. E., Perry, M., Park, J., Younus, A., Gutin, A., Foster, C. S., Scardino, P., Lanchbury, J. S., & Stone, S.
- Venue
- British Journal of Cancer
- Published
- 2012-02-23
- Volume
- 106
- Issue
- 6
- Pages
- 1095-1099
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2158099560
- Cited by
- 364
- References
- 13
- FWCI
- 27.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.